Found: 5
Select item for more details and to access through your institution.
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity.
- Published in:
- Obesity (19307381), 2023, v. 31, n. 9, p. 2249, doi. 10.1002/oby.23842
- By:
- Publication type:
- Article
The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2318, doi. 10.1111/dom.15546
- By:
- Publication type:
- Article
Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF‐36 with Australian weights.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 4, p. 1171, doi. 10.1111/dom.15426
- By:
- Publication type:
- Article
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2142, doi. 10.1111/dom.15090
- By:
- Publication type:
- Article
Tipping-point transition from transient to persistent inflammation in pancreatic islets.
- Published in:
- NPJ Systems Biology & Applications, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41540-024-00427-4
- By:
- Publication type:
- Article